Skip to main content
Close up of a hand using a tablet

Announcements

Removing Barriers to Fracture Prevention: CDA Recommends Expanded Access to Romosozumab

October 8, 2026

Following an extraordinary community engagement effort which began in May 2025, today marks a significant milestone in expanding access to treatment for Canadians living with osteoporosis at high risk for fractures. Canada’s Drug Agency (CDA) has issued a positive recommendation for romosozumab (Evenity), an important bone-building treatment for osteoporosis, to include patients with prior exposure to other osteoporosis therapies.

As the outcome of a review conducted through its Request for Advice (RfA) process, CDA has recommended that public drug plans should update the reimbursement initiation criteria for romosozumab so that access is no longer contingent on a patient being considered “treatment naïve.” This change, which aligns with current clinical treatment guidelines, could help reduce barriers to care and improve timely access to treatment for Canadians at high risk of fracture.

“Osteoporosis Canada would like to thank CDA and the public drug programs for initiating the RfA process, considering the community’s voice in their deliberations, and for recognizing the importance of ensuring timely and equitable access to this advancement in fracture prevention for osteoporosis patients across the country,” said Dr. Famida Jiwa, CEO of Osteoporosis Canada.

Fragility fractures can have life-altering consequences, including loss of mobility, independence, and quality of life. The eligibility restriction limiting access to romosozumab has been an issue affecting many vulnerable members of the osteoporosis community across Canada. Osteoporosis Canada, together with its Scientific Advisory Council, has worked to highlight the challenges these barriers create for people at high risk of fracture and advocate for expanded access to this important therapy.

“Patients at high risk of fracture need timely access to the most effective treatment options available,” said r. David Kendler, MD, Emeritus Professor of Medicine (Endocrinology), University of British Columbia. “By clarifying access criteria and removing the ‘treatment naïve’ requirement, this recommendation better matches the clinical evidence, and supports more consistent and equitable reimbursement decisions across Canada and helps ensure patients can access the most appropriate therapy when it is needed.”

Osteoporosis Canada also thanks all those who contributed to the RfA process, including the eight clinician groups and individual patients who shared their experiences directly with CDA.

“I know first-hand the enormous pain and suffering that comes with fractures. With Evenity, my bone health has improved to the extent that I can continue to live a healthy and active lifestyle without the fear of fractures,” said Susan Fraser, who was diagnosed with severe osteoporosis of the spine at age 58. “This treatment has made an immeasurable difference in my life, as I hope it will for others, now and in the future.”

While this recommendation represents meaningful progress, it does not automatically translate into expanded access to romosozumab for patients across the country. Osteoporosis Canada and the clinician community will continue to work collaboratively with provincial governments and public drug plans across Canada to encourage timely adoption of the updated reimbursement criteria.

To read the full recommendation from CDA, visit: https://www.cda-amc.ca/sites/default/files/DRR/2026/SF0925-Romosozumab_Final_Rec.pdf


OC MAKES THE NEWS – RECENT ITEMS

DENOZA® is now available in Canada

September 25, 2026

Latest News DENOZA® (denosumab injection), a biosimilar from Apotex, is now available in Canada September 25, 2026 PrDENOZA® is indicated for the treatment of postmenopausal osteoporosis, and to increase bone […]

Healthcare Professional Educational Events

August 19, 2026

Healthcare Professional Educational Events August 19, 2026 View the following information for two events for the healthcare professional: Canadian Symposia on Rare Bone Diseases 2026 ISCD Quality Bone Densitometry: for […]

Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones

July 7, 2026

Latest News Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones July 7, 2026 Fragility fractures are a major and growing health burden, with significant personal and […]

© Osteoporosis Canada, 2026
Charitable Registration No. 89551 0931 RR 0001